# Versarien Acquisition of CVD Assets and IP from Hanwha Aerospace

- Link: https://www.directorstalkinterviews.com/versarien-acquisition-of-cvd-assets-and-ip-from-hanwha-aerospace/412949839
- Published: 2020-12-22T07:17:46+00:00
- Author: Giles

**Versarien plc** (LON:VRS), the advanced materials engineering group, has announced
that the Company has agreed to acquire certain graphene production related assets
and intellectual property from South Korea based Hanwha Aerospace Co. Ltd, for consideration
comprising 11,000,000 ordinary shares of 1 pence each in the Company. The consideration
is equivalent to £4.34 million at the 39.475 pence per Ordinary Share closing mid-
market price on 18 December 2020.

In addition, the Company has entered into a subscription agreement with Lanstead
Capital Investors LP to subscribe for 8,750,000 new Ordinary Shares at 40 pence 
per Subscription Share raising gross proceeds of £3.50 million, the proceeds of 
which will be used for an additional sharing agreement with Lanstead, as described
below.

**Highlights**

·    Versarien has agreed to acquire certain assets and intellectual property that
form the South Korea based chemical vapor deposition (“CVD”) activities of Hanwha
Aerospace Co. Ltd for a consideration of 11,000,000 new Consideration Shares.

·    The Acquisition comprises a portfolio of over 100 patents and patent rights,
many originally developed by Samsung in South Korea, covering CVD graphene manufacturing
methods and related applications, together with manufacturing equipment suitable
for producing high quality large format electronics grade graphene.

·    Subscription for 8,750,000 Subscription Shares by Lanstead, who currently hold
approximately 7.57% of the Company’s issued share capital, at the Issue Price to
raise gross proceeds of £3.50 million. The £3.50 million gross proceeds of the Lanstead
Subscription will be pledged by the Company pursuant to an additional sharing agreement
with Lanstead (the “Sharing Agreement”), following the one entered into in March
2020, details of which were notified in the Company’s announcements of 23 March 
and 6 April 2020.

·    The Sharing Agreement, details of which are set out below, entitles the Company
to receive back the proceeds on a pro rata monthly basis over a period of 18 months,
subject to adjustment upwards or downwards each month depending on the Company’s
share price. The net proceeds received by the Company from the Sharing Agreement
will be used primarily to establish operations in South Korea following the Acquisition,
as well as for the Company’s general working capital purposes.

> **Neill Ricketts, Chief Executive Officer of Versarien, commented: **
> “We are delighted to have agreed the Acquisition which complements our existing
> portfolio of graphene materials technology. In particular, it will provide us 
> with access to patented technology and equipment to produce high quality single
> and dual layer graphene that has particular applications in the electronics sector,
> together with other areas, including in relation to some of our existing collaborations.
> The Acquisition will also help facilitate our planned future Asian development.
> “We are pleased that we have received additional support from Lanstead to provide
> the funding and additional working capital required for our international expansion
> strategy.”

**The Acquisition**

The Acquisition comprises certain assets and intellectual property (“IP”) that forms
the South Korea based CVD activities of Hanwha Aerospace, part of the Hanwha Group.

As part of the Acquisition, Versarien is acquiring over 100 patents that cover a
number of areas including graphene manufacture and certain graphene applications
that the Directors believe will complement the Group’s existing 2D materials portfolio.
These patents cover areas including using CVD methods to produce high quality single
and dual layer graphene and methods to produce graphene based thin film laminates
that the Directors believe will have potential applications in the electronics sector,
amongst others.

Additionally, the Acquisition comprises manufacturing equipment suitable for producing
high quality large format electronics grade graphene. The Company plans to establish
operations in South Korea via its new subsidiary which will be overseen initially
by Versarien’s Head of International Strategy and Government Relations, Matt Walker.

The consideration for the Acquisition is being satisfied through the issue of the
11,000,000 Consideration Shares to Hanwha Aerospace. Hanwha Aerospace have agreed
not to dispose of 2,000,000 of the Consideration Shares for a minimum period of 
six months and not to dispose of 2,000,000 of the Consideration Shares for a minimum
period of 12 months.

Completion of the Acquisition is conditional on the admission to AIM of all of the
Consideration Shares. Following Second Admission (as defined below), Hanwha Aerospace
will hold approximately 5.79% of the Company’s issued ordinary share capital, as
enlarged by the issue of the Consideration Shares, the Subscription Shares and the
Value Payment Shares_._

**T****he ****Lanstead ****Subscription and the ****Lanstead ****Sharing Agreement**

**Existing Lanstead Sharing Agreement**

As announced on 23 March 2020, Lanstead subscribed for 15,000,000 Ordinary Shares
at an issue price of 40 pence per Ordinary Share and the Company entered into a 
related sharing agreement to receive the proceeds on a pro rata basis over 24 months.
The Company has, as expected, to date received seven of the 24 settlements due under
the March 2020 Lanstead Sharing Agreement providing gross proceeds to the Company
of approximately £1.42 million with the proceeds from the remaining 17 settlements
receivable on a monthly basis as they fall due, in addition to the proceeds from
the additional Lanstead sharing agreement described below.

If the Company’s share price had been equal to the average Benchmark Price of 53.33p
for the seven settlements received to date, then it would have received gross proceeds
to date of £1.75 million from the March 2020 Lanstead Sharing Agreement.

**Additional Lanstead Subscription and Sharing Agreement**

Pursuant to this additional subscription agreement between the Company and Lanstead,
Lanstead has conditionally agreed to subscribe for 8,750,000 Ordinary Shares at 
the issue price of 40 pence for gross proceeds of £3.50 million before expenses.

The Lanstead Subscription is conditional, _inter alia_, on Admission and there being:(
i) no breach of certain customary warranties given by the Company to Lanstead at
any time prior to Admission; and (ii) no force majeure event occurring prior to 
Admission.

As part of the Lanstead Subscription, the Company will enter into the Sharing Agreement,
pursuant to which the £3.50 million gross proceeds of the Lanstead Subscription 
will be pledged to Lanstead under the Sharing Agreement pursuant to which Lanstead
will then make, subject to the terms and conditions of that Sharing Agreement, monthly
settlements (subject to adjustment upwards or downwards) to the Company over 18 
months, as detailed below. As a result of entering into the Sharing Agreement, the
aggregate gross amount received by the Company under the Lanstead Subscription and
the related Sharing Agreement may be more or less than £3.50 million, as further
explained below.

The Sharing Agreement will enable the Company to benefit from any share price appreciation
over the average Benchmark Price of 53.33 pence (as defined below). However, if 
the Company’s share price is less than the average Benchmark Price then the amount
received by the Company under the Sharing Agreement will be less than the gross 
proceeds of the Lanstead Subscription which were pledged by the Company to Lanstead
at the outset.

The Sharing Agreement provides that the Company will receive 18 monthly settlement
amounts as measured against an average benchmark share price of 53.33 pence per 
Subscription Share. The monthly settlement amounts for the Sharing Agreement are
structured to commence approximately two months following the admission to trading
on AIM of the Lanstead Subscription Shares.

If the measured share price, calculated as the average volume weighted share price
of the Company’s Ordinary Shares over a period of 20 trading days prior to the monthly
settlement date, exceeds the Benchmark Price, the Company will receive more than
100 per cent. of that monthly settlement due on a _pro rata_ basis according to 
the excess of the Measured Price over the Benchmark Price. There is no upper limit
placed on the additional proceeds receivable by the Company as part of the monthly
settlements and the amount available in subsequent months is not affected. Should
the Measured Price be below the Benchmark Price, the Company will receive less than
100 per cent. of the monthly settlement calculated on a _pro rata_ basis and the
Company will not be entitled to receive the shortfall at any later date.

For example, if on a monthly settlement date the calculated Measured Price exceeds
the Benchmark Price by 10 per cent., the settlement on that monthly settlement date
will be 110 per cent. of the amount due from Lanstead on that date. If on the monthly
settlement date the calculated Measured Price is below the Benchmark Price by 10
per cent., the settlement on the monthly settlement date will be 90 per cent. of
the amount due on that date. Each settlement as so calculated will be in final settlement
of Lanstead’s obligation on that settlement date.

Assuming the Measured Price equals the average Benchmark Price on the date of each
and every monthly settlement, the Company would receive aggregate proceeds of £3.50
million (before expenses) from the Lanstead Subscription and Sharing Agreement. 
If the Measured Price is less than the Benchmark Price on the date of each and every
monthly settlement, the Company would receive aggregate proceeds of less than £3.50
million (before expenses). If the Measured Price is more than the Benchmark Price
on the date of each and every monthly settlement, the Company would receive aggregate
proceeds of more than £3.50 million (before expenses).

The Company will pay Lanstead’s legal costs incurred in the Lanstead Subscription
and in entering into the Sharing Agreement and, in addition, has agreed to issue
to Lanstead 437,500 new Ordinary Shares in connection with entering into the Sharing
Agreement at a price of 40p per share, a deemed consideration of £175,000.

In no event will fluctuations in the Company’s share price result in any increase
in the number of Lanstead Subscription Shares issued by the Company or received 
by Lanstead.

In total, Lanstead will be issued with 9,187,500 new Ordinary Shares, comprising
the Lanstead Subscription Shares and the Value Payment Shares, pursuant to the Lanstead
Subscription. No shares, warrants or additional fees are owed to Lanstead at any
point during this agreement other than those disclosed above. Following Second Admission(
as defined below), Lanstead will hold approximately 11.60% of the Company’s issued
ordinary share capital, as enlarged by the issue of the Consideration Shares, the
Subscription Shares and the Value Payment Shares.

In order for shareholders to further understand the possible outcomes from the Sharing
Agreement, the Company sets out below some examples of the amount of proceeds that
it would receive in a monthly settlement from the Sharing Agreement, depending on
the 20 day average volume weighted share price of the ordinary shares of the Company
in the period prior to the settlement. This does not include the amounts due to 
the Company from the ongoing March 2020 Lanstead Sharing Agreement, details of which
were contained in the Company’s announcements on 23 March and 6 April 2020.

| Measured Price (20 day volume weighted average share price) | Monthly gross proceeds #2 | Approximate monthly net proceeds after all costs #3 | 
| 80 pence | £291,685 | £273,004 | 
| 60 pence | £218,764 | £201,906 | 
| 53.33 pence #1 | £194,444 | £178,194 | 
| 40 pence | £145,842 | £130,807 | 
| 20 pence | £72,921 | £59,709 |

#1 the Benchmark Price for the Sharing Agreement

_#2 being the number of __Lanstead __Subscription Shares multiplied by the Subscription
Price multiplied by the Measured Price divided by the Benchmark Price (being a premium
of 33.33% to the Subscription Price) and divided by __18__ settlements_

_#3_**_ _**_assuming this is the average Measured Price over the __18__ months of
the Sharing Agreement_

The proceeds receivable by the Company over the 18 month duration of the Sharing
Agreement will be net of the cost of £175,000 incurred by the Company in entering
into the Sharing Agreement with Lanstead, satisfied by the issue of the Value Payment
Shares to Lanstead, approximately £30,000 of other costs incurred by Versarien in
connection with the Lanstead Subscription and Sharing Agreement, together with advisory
fees paid to a third party adviser to Versarien of 2.5% of the amounts received 
under the Sharing Agreement.

The Directors believe that the Sharing Agreement provides a number of benefits to
Versarien and its shareholders including: the certainty of near-term funding albeit
the quantum is dependent on the Versarien share price; the opportunity to benefit
from positive future share price performance; and that the amount of shares issued
are fixed, together with the cost of their issue. There are corresponding risks 
that the aggregate amount of cash proceeds received under the Sharing Agreement 
might be less than the original subscription and there is uncertainty as to the 
amount that the Company might receive.

Whilst the Company could potentially raise a greater sum of money per share issued
from a future placing of shares, if the share price rises above the Benchmark Price,
when compared to the proceeds from the Sharing Agreement, this would be dependent
on a number of factors such as the willingness of investors to participate in any
placing, the ability to achieve a placing at an appropriate discount and the ability
of the Company to limit the costs of any such placing. The Directors believe that
the proceeds the Company will receive from the Sharing Agreement with Lanstead outweigh
the risks associated with any such theoretical placing given the uncertainty of 
when such a placing may be possible and the uncertainty of achieving a positive 
outcome when compared with the possible proceeds from the Sharing Agreement.

**Related Party Transaction **

For the purposes of the Sharing Agreement, Lanstead has been treated as a related
party of the Company. The Directors of the Company (all of whom are independent 
of Lanstead), having consulted with SP Angel Corporate Finance LLP, the Company’s
nominated adviser, consider that the Sharing Agreement is fair and reasonable insofar
as Shareholders are concerned.

**Admission and ****Total Voting Rights**

The Consideration Shares (11,000,000 Ordinary Shares), the Subscription Shares (
8,750,000 Ordinary Shares) and the Value Payment Shares (437,500 Ordinary Shares)
will rank _pari passu_ with the existing Ordinary Shares.

Application has been made for the admission to trading on AIM for 9,000,000 of the
Consideration Shares, the Subscription Shares and the Value Payment Shares (“First
Admission”). It is expected that First Admission will become effective on or around
23 December 2020.  Application has been made for the remaining 2,000,000 Consideration
Shares to be admitted to trading on AIM (“Second Admission”).  It is expected that
Second Admission will become effective on or around 24 December 2020.

Following the First Admission, the Company will have 187,869,790 ordinary shares
of 1p each in issue. The figure of 187,869,790 may be used by the Company’s shareholders
as the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the Company
under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

Following the Second Admission, the Company will have 189,869,790 ordinary shares
of 1p each in issue. The figure of 189,869,790 may be used by the Company’s shareholders
as the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the Company
under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

Share on:
